Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | ACLY | P53396 | 5/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988237 | 0.91 | METAP2 (0.53) | TSHRMETAP2ACLYFABP4 | |
| SCHEMBL3982432 | 0.89 | TSHR (0.54) | TSHRMETAP2ACLYALDH1A1KDM4E | |
| SCHEMBL3982582 | 0.88 | TSHR (0.47) | TSHRMETAP2ACLYFABP4KMT2A | |
| SCHEMBL3979797 | 0.87 | TSHR (0.49) | TSHRMETAP2ACLYALDH1A1KDM4E | |
| SCHEMBL3988657 | 0.85 | METAP2 (0.56) | TSHRMETAP2ACLYFABP4ALDH1A1 | |
| SCHEMBL3988184 | 0.83 | TSHR (0.47) | TSHRMETAP2ACLYFABP4ALDH1A1 | |
| SCHEMBL1646666 | 0.81 | POLB (0.38) | TSHRALDH1A1KMT2APOLBMAPT | |
| SCHEMBL3980835 | 0.79 | METAP2 (0.56) | TSHRMETAP2ACLYALDH1A1KDM4E | |
| SCHEMBL3982813 | 0.79 | METAP2 (0.52) | TSHRMETAP2ACLYFABP4ALDH1A1 | |
| SCHEMBL3986601 | 0.78 | METAP2 (0.53) | TSHRMETAP2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TSHR 4446/4885METAP2 1/4885ACLY 2986/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TSHR 4446/4885METAP2 1/4885ACLY 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.